Jennerex, Transgene deal

Jennerex granted Transgene exclusive rights to develop and commercialize JX-594 in Europe, the Commonwealth of Independent States and the Middle East. The partners will co-develop the recombinant vaccinia virus (TK-deletion plus GM-CSF) worldwide, with Transgene responsible for costs and clinical development in its licensed territories. The companies plan to conduct a Phase IIb/III trial in hepatocellular carcinoma (HCC) and a Phase II trial to treat colorectal cancer, but have yet to establish a timeline for starting the trials. JX-594 has Orphan Drug designation in Europe to treat HCC. ...